These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 10027497)

  • 21. Beta-blockers in heart failure. Do they improve the quality as well as the quantity of life?
    Fowler MB
    Eur Heart J; 1998 Dec; 19 Suppl P():P17-25. PubMed ID: 9886708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carvedilol.
    Can Fam Physician; 1999 May; 45():1199-202, 1205-9. PubMed ID: 10349064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Now there are four: Carvedilol takes its place in therapeutical line-up for heart failure.
    Phillips L
    Hosp Technol Ser; 1997 Mar; 16(3):6-7. PubMed ID: 10166705
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of carvedilol on mortality and morbidity in patients with chronic heart failure.
    Circulation; 1996 Aug; 94(4):592. PubMed ID: 8772669
    [No Abstract]   [Full Text] [Related]  

  • 25. Role of carvedilol in atrial fibrillation: insights from clinical trials.
    Gheorghiade M; Lukas MA
    Am J Cardiol; 2004 May; 93(9A):53B-7B. PubMed ID: 15144939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carvedilol and metoprolol European trial: do the results merit challenge?
    Smith KM
    Am J Health Syst Pharm; 2004 Jun; 61(12):1289-93. PubMed ID: 15259762
    [No Abstract]   [Full Text] [Related]  

  • 27. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
    Packer M; Bristow MR; Cohn JN; Colucci WS; Fowler MB; Gilbert EM; Shusterman NH
    N Engl J Med; 1996 May; 334(21):1349-55. PubMed ID: 8614419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Doxorubicin-induced cardiomyopathy treated with carvedilol.
    Fazio S; Palmieri EA; Ferravante B; Bonè F; Biondi B; Saccà L
    Clin Cardiol; 1998 Oct; 21(10):777-9. PubMed ID: 9789703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Commentary on the Carvedilol or Metoprolol European Trial (COMET).
    Poole-Wilson PA
    Am J Cardiol; 2004 May; 93(9A):40B-2B. PubMed ID: 15144936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carvedilol for heart failure: more than just a beta-blocker?
    Cleland JG
    Br J Hosp Med; 1997 Nov 19-Dec 9; 58(10):493-7. PubMed ID: 10193451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
    Lancet; 1997 Feb; 349(9049):375-80. PubMed ID: 9033462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Severe heart failure. Carvedilol lowers mortality].
    MMW Fortschr Med; 2001 Mar; 143(9):58. PubMed ID: 11288541
    [No Abstract]   [Full Text] [Related]  

  • 33. [Long term use of a non-selective beta-blocker with vasodilating properties carvedilol in patients with severe heart failure].
    Zaikin SY; Iosava IK; Vasechkin SS; Gruzdev AK; Sidorenko BA
    Kardiologiia; 2002; 42(4):33-6. PubMed ID: 12494164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A fairer comparison between carvedilol and metoprolol is still to be done].
    Johnsson G; Aberg J
    Lakartidningen; 2003 Oct; 100(44):3543-4, 3544-5. PubMed ID: 14651018
    [No Abstract]   [Full Text] [Related]  

  • 35. Carvedilol in the treatment of chronic heart failure: lessons from the Carvedilol Or Metoprolol European Trial.
    Kveiborg B; Major-Petersen A; Christiansen B; Torp-Pedersen C
    Vasc Health Risk Manag; 2007; 3(1):31-7. PubMed ID: 17583173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The effectiveness of carvedilol in heart failure].
    Kárpáti K; Brodszky V; Farsang C; Jermendy G; Vándorfi G; Zámolyi K; Gulácsi L
    Orv Hetil; 2006 Oct; 147(40):1931-7. PubMed ID: 17111685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Pediatric Randomized Carvedilol Trial in Children with Heart Failure: rationale and design.
    Shaddy RE; Curtin EL; Sower B; Tani LY; Burr J; LaSalle B; Boucek MM; Mahony L; Hsu DT; Pahl E; Burch GH; Schlencker-Herceg R
    Am Heart J; 2002 Sep; 144(3):383-9. PubMed ID: 12228773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of carvedilol in pediatric heart failure.
    Greenway SC; Benson LN
    Cardiovasc Hematol Disord Drug Targets; 2006 Mar; 6(1):35-42. PubMed ID: 16724934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure.
    Ruffolo RR; Feuerstein GZ
    Cardiovasc Drugs Ther; 1997 May; 11 Suppl 1():247-56. PubMed ID: 9211017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
    Circulation; 1995 Jul; 92(2):212-8. PubMed ID: 7600653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.